Outcomes of nucleos(t)ide analogue discontinuation following finite xalnesiran-based therapies in chronic hepatitis B.

JHEP RepJul 15, 2026 (epub)
Clinical ResearchGastroenterologyOpen access

Cong Cheng, Qing Xie, Edward Gane et al.

✦ AI-curated · Sources linked

In 30 seconds

This phase II randomized controlled trial evaluated the outcomes of nucleos(t)ide analogue (NA) discontinuation in 121 virologically suppressed participants with chronic hepatitis B (CHB) following xalnesiran-based therapies. Of the 40 participants who discontinued NA, 5 achieved sustained HBsAg loss and undetectable HBV DNA. The study highlights the potential for safe NA discontinuation strategies in CHB treatment.

Key findings

  • 48% of participants met NA stopping criteria, with 33% actually discontinuing NA.
  • Among those who discontinued, 43% met criteria to restart NA, while 60% remained off NA by study's end.
  • 5 participants achieved and maintained HBsAg loss and undetectable HBV DNA while off NA.
  • 48% of those who discontinued NA experienced virological relapse, with 8% developing clinical relapse.

Why it matters

Understanding the outcomes of NA discontinuation is crucial for optimizing treatment strategies in chronic hepatitis B. This study provides insights into managing NA withdrawal safely, which is essential for achieving functional cures in patients.

Source

PubMed · PMID 42456805Free full text on PubMed Central

Published in JHEP Rep. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.